In just a few years, pharma's top launches of 2014 have amassed huge sales and reshaped treatment—and they're now among the biggest launches ever.
Rare disease biotech Ultragenyx has its first FDA nod in Mepsevii, an enzyme therapy expected to carry a high price to treat a tiny group of patients.
AstraZeneca is about to find out whether its third-to-market respiratory biologic can stand out from a crowd that includes rivals GSK and Teva.
Johnson & Johnson's Xarelto has more results to back up its artery disease case—and help it extend its indication lead over the competition.
Launched for lung cancer awareness month in November, the “tALK+” (Talk Positive) campaign focuses on the ALK-positive form of lung cancer.
Will pharma learn to love Twitter now that it’s doubled its character limit to 280?
If recent numbers—and a new doctor survey—are any indication, Tesaro's Zejula has the lead in ovarian cancer. But that could change.
Pharma can usually look back at FDA enforcement letters for insight into the agency's thinking on marketing communications. Not this year.
The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.
Novartis’ Cosentyx currently leads a crop of immunology meds from a who’s who of Big Pharma. And the company intends to keep it that way.